AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20619378
Drug: 240 microg
RxNorm normalized name: Latanoprostene bunod 240 microgram/mL eye drops solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 microg dose
Trial: 20624109
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (three doses of 4 g)
Trial: 20626754
Drug: Bendamustine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (120 mg/m² on days 1-2 of a 21-day cycle, for up to six cycles)
Trial: 20630061
Drug: Temsirolimus administered
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus administered intravenously at 25 mg weekly (Study A)
Trial: 20630061
Drug: Everolimus administered
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus administered orally at 30 mg weekly and erlotinib at 150 mg daily (Study B)
Trial: 20633428
Drug: ECT (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT (6 bilateral treatments, outpatient, twice-weekly)
Trial: 20634373
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m(2) on days 1, 29, 57 and 85; Fludarabine orally, 40 mg/m(2) on days 1-5, 29-34, 57-61 and 85-89
Trial: 20634373
Drug: Fludarabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and rituximab combination therapy
Trial: 20634785
Drug: Diannexin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diannexin treatment
Trial: 20636419
Drug: Inadequate or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate or no antimicrobial treatment at origin
Trial: 20638196
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of CHOP chemotherapy and radiation to a dose of 45 Gy in 25 fractions using a shrinking field technique
Trial: 20650686
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression
Trial: 20650686
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy
Trial: 20651074
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/d with a 3-month low-dose prednisone taper
Trial: 20653948
Drug: IMP321 (LAG-3Ig)
RxNorm normalized name: Anti-lag-3 monoclonal antibody regn3767
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP321 (LAG-3Ig) administered subcutaneously every two weeks for 24 weeks (12 injections) alongside paclitaxel (80 mg/m2 weekly for 3 weeks out of 4)
Trial: 20659883
Drug: Initial serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial serum glucose level >140 mg/dl
Trial: 20660050
Drug: Thymidine analogs
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymidine analogs (iododeoxyuridine or bromodeoxyuridine) administered 8 days to 4 years prior to death.
Trial: 20662793
Drug: Gemcitabine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine combined with carboplatin (i.v. gemcitabine at 1000 mg/m² on days 1 and 8, and i.v. carboplatin at AUC 5 on day 1 of a 21-day cycle)
Trial: 20663944
Drug: Oral busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral busulfan 12 mg/kg plus melphalan 140 mg/m2
Trial: 20663944
Drug: Melphalan 200
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 200 mg/m2
Trial: 20664181
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for MCI patients combining psychoeducation, cognitive rehabilitation, and cognitive-behavioral therapy.
Trial: 20666569
Drug: Low-dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose ASA (75-325 mg daily)
Trial: 29619769
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (specifics not provided)
Trial: 20668228
Drug: Preparative chemotherapy
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative chemotherapy regimen
Trial: 20671408
Drug: Metformin (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1250 mg/day)
Trial: 20675064
Drug: Pulsed-dose-rate (PDR)
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed-dose-rate (PDR) brachytherapy, 49.8 Gy in 83 consecutive fractions of 0.6 Gy each hour, total treatment time 3 to 4 days.
Trial: 20675064
Drug: High-dose-rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate (HDR) brachytherapy, 32 Gy in eight fractions of 4 Gy, twice daily.
Trial: 20675064
Drug: Antihormonal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihormonal treatment (AHT) applied (91% of patients)
Trial: 20675064
Drug: No antihormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihormonal treatment (AHT not applied, 9% of patients)
Trial: 20677285
Drug: Early allograft
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early allograft dysfunction (EAD) defined by bilirubin >or=10mg/dL on day 7, INR >or=1.6 on day 7, and ALT/AST >2000 IU/L within the first 7 days.
Trial: 20681993
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) in obese men
Trial: 20683637
Drug: 17-AAG (17-allylamino-17-demethoxygeldanamycin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-AAG (17-allylamino-17-demethoxygeldanamycin), administered weekly, intravenous
Trial: 20685491
Drug: Calcium 1200
RxNorm normalized name: Premier Value Calcium 1200 + D3 Extended-Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 1200 to 2000 mg/d
Trial: 20689350
Drug: Receptive music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptive music therapy
Trial: 20696979
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with abnormal anticardiolipin antibody levels
Trial: 20697802
Drug: Sagopilone 16
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sagopilone 16 mg/m²
Trial: 20697802
Drug: Sagopilone 22
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sagopilone 22 mg/m²
Trial: 20697802
Drug: Sagopilone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sagopilone (both doses)
Trial: 20698927
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus vitamin B12 treatment (0.8 mg folic acid, 0.4 mg vitamin B12, 40 mg vitamin B6)
Trial: 20698927
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus vitamin B12 treatment
Trial: 20701823
Drug: Quetiapine (dose-dependent)
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine (dose-dependent)
Trial: 20701823
Drug: Quetiapine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (high doses)
Trial: 20701823
Drug: Quetiapine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (low doses)
Trial: 20702138
Drug: FOLFOXIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m², oxaliplatin 85 mg/m², folinate 200 mg/m², fluorouracil 3200 mg/m² for 48 h continuous infusion)
Trial: 20702138
Drug: FOLFOXIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI plus bevacizumab (induction treatment for a maximum of 6 months, followed by maintenance treatment with bevacizumab 5 mg/kg every 2 weeks)
Trial: 20702138
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with bevacizumab (5 mg/kg every 2 weeks)
Trial: 20708849
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a total dose of 60 Gy in three fractions for peripheral lesions and four fractions for central lesions.
Trial: 20710052
Drug: Etravirine 400
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine 400 mg once daily with tenofovir disoproxil fumarate/emtricitabine 300/200 mg once daily from days 1-14; darunavir/ritonavir 800/100 mg once daily added on days 15-28
Trial: 20710052
Drug: Etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 200 mg twice daily (post-hoc analysis)
Trial: 20710088
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment program including a 3-phase progressive strengthening program, manual stretching, thrust and nonthrust manipulation to the shoulder and spine, patient education, activity modification, and a daily home exercise program of stretching and strengthening.
Trial: 20710088
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment program
Trial: 20712386
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg/day, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day as needed
Trial: 20712386
Drug: Olmesartan medoxomil/hydrochlorothiazide
RxNorm normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40/25 mg/day
Trial: 20713833
Drug: Liquor carbonis
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquor carbonis distillate solution
Trial: 20713962
Drug: Eliglustat tartrate
RxNorm normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat tartrate 50 or 100 mg twice daily for 2 years
Trial: 20716591
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) plus Erlotinib (200 mg/day for non-EIAEDs; 500 mg/day for EIAEDs)
Trial: 20716591
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) plus Erlotinib
Trial: 20718769
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) levels
Trial: 20719837
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH) therapy
Trial: 20719839
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment (hydrocortisone 26%, prednisolone 43%, dexamethasone 19%, combination 10%)
Trial: 20721537
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 to 30 mg/day)
Trial: 20724537
Drug: M-dex +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-dex + lenalidomide 15 mg/day
Trial: 20724742
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of albuterol plus tiotropium
Trial: 20725912
Drug: Colesevelam treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam treatment
Trial: 20727190
Drug: Multipeptide vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multipeptide vaccine in incomplete Freund's adjuvant (IFA)
Trial: 20729251
Drug: Decision aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aid intervention to inform and support the choice between tube feeding and assisted oral feeding
Trial: 20730365
Drug: Aquatic physical
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic physical therapy for 10 minutes, involving movements to stimulate flexor posture and postural organization.
Trial: 20731625
Drug: 4 h
RxNorm normalized name: Type 4 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 h graded infusion of intralipid (20%)/heparin
Trial: 20732372
Drug: Aripiprazole (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5-20 mg/day for 8 weeks)
Trial: 20732372
Drug: Benzamide antipsychotics
RxNorm normalized name: Benzamide antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzamide antipsychotics (amisulpride and sulpiride)
Trial: 20739388
Drug: motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: motesanib 125 mg once daily for up to 48 weeks
Trial: 20797845
Drug: L19-IL2 (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19-IL2 (22.5 Mio IU IL2 equivalent dose)
Trial: 20798939
Drug: Docetaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (80 mg/m2 as a 1-h infusion in a 21-day cycle for 3 cycles)
Trial: 20798939
Drug: Dexamethasone (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (total dose of 45 mg, with 15 mg before docetaxel infusion and 30 mg before CYP3A assessment)
Trial: 20798939
Drug: Midazolam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (7.5 mg oral)
Trial: 20809967
Drug: Neostigmine 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 70 μg/kg with glycopyrrolate 14 μg/kg
Trial: 20811392
Drug: STA-21 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA-21 ointment
Trial: 20812791
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications (study drug)
Trial: 20812791
Drug: Previous antipsychotic
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous antipsychotic medication (used prior to enrollment)
Trial: 20812850
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (types 6, 11, 16, and 18), administered 0.5 mL intramuscularly at entry, week 8, and week 24.
Trial: 20814317
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (150-300 mg/d)
Trial: 20815703
Drug: Blocking antibodies
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking antibodies (measured by HBGA blocking assay)
Trial: 20816019
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell based cancer vaccine (MelCancerVac)
Trial: 20816040
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy
Trial: 20816873
Drug: Sustained ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained ventricular arrhythmia (VA) with appropriate ICD therapies
Trial: 20819968
Drug: Aerobic interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic interval training (4 x 4 minutes at 90% of maximal heart rate, 40 minutes total, twice per week for 13 weeks)
Trial: 20822542
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg + methotrexate (MTX)
Trial: 20822542
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg + MTX
Trial: 20823423
Drug: Bortezomib-doxorubicin-dexamethasone (BDD)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-doxorubicin-dexamethasone (BDD) therapy
Trial: 20823436
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1 doses of PCV-7 at 2, 4, and 11 months
Trial: 20831796
Drug: Trazodone (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50-300 mg/day)
Trial: 20837883
Drug: LCI699 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (0.5 mg BID)
Trial: 20837883
Drug: LCI699 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (1.0 mg BID)
Trial: 20837883
Drug: LCI699 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (4 weeks treatment)
Trial: 20837940
Drug: Temsirolimus 25-mg
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25-mg weekly (Group A)
Trial: 20837940
Drug: Temsirolimus 25-mg
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25-mg weekly (Group B)
Trial: 20837940
Drug: Temsirolimus 25-mg
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25-mg weekly (Group C)
Trial: 20838998
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg orally once daily for 48 weeks
Trial: 20840760
Drug: CNI-free combination
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-free combination therapy (basiliximab, MMF, steroids and delayed Sirolimus)
Trial: 20841416
Drug: Propofol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (50 μg/kg/min)
Trial: 20841509
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab plus alemtuzumab (10 mg of alemtuzumab subcutaneously on days 1 to 3, plus 100 mg of rituximab intravenously weekly in 4 doses)
Trial: 20843246
Drug: INCB018424 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB018424 (15 mg twice daily, individualized dose titration)
Trial: 20843592
Drug: Thujone-free wormwood
RxNorm normalized name: Wormwood
DrugBank: Wormwood (DB14291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thujone-free wormwood preparation (1.8 g/d for 6 months)
Trial: 20844233
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg orally per day for 3 weeks
Trial: 20846606
Drug: Systolic and
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systolic and diastolic deformation indexes (E(cc) and E(cc)/s)
Trial: 20851682
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg daily in 4-week cycles)
Trial: 20854181
Drug: H1-Coil repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1-Coil repetitive transcranial magnetic stimulation (rTMS) at 20 Hz, 2 s on, 20 s off, totaling 1680 stimuli, daily for four weeks
Trial: 20854821
Drug: S-adenosyl methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl methionine (SAMe) 1600 mg daily for 2 weeks followed by peginterferon and ribavirin for 48 weeks
Trial: 20855799
Drug: darunavir-ritonavir, 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir-ritonavir, 600/100 mg twice daily, plus an investigator-selected optimized background regimen
Trial: 20859150
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 3.9 g/d for up to 5 days per menstrual cycle through six cycles
Trial: 20860020
Drug: Darifenacin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin treatment
Trial: 20862748
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally, once daily, on Schedule 4/2
Trial: 20863431
Drug: octagam 10%
RxNorm normalized name: Octagam 10% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octagam 10% 1 g/kg/day on two consecutive days; maximum infusion rate of 0·12 ml/kg/minute
Trial: 20874827
Drug: Peptide LY6K-177,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide LY6K-177, peptide TTK-567, and CpG-7909 (level-1; 0, level-2; 0.02, level-3; 0.1 mg/kg)
Trial: 20875102
Drug: IDD-3 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDD-3 (8 doses of autologous monocyte-derived matured DC with GM-CSF and IL-13, pulsed with melanoma cell line lysates, matured with interferon gamma)
Trial: 20879880
Drug: Reduced chemotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced chemotherapy (4 cycles for favorable features, 8 cycles for unfavorable features)
Trial: 20879880
Drug: Reduced chemotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced chemotherapy